Home » Newsletters » BioWorld Science

BioWorld Science

March 23, 2004

View Archived Issues

Boosting endogenous interferon for hepatitis C therapy

Alutard(R) SQ house dust mite vaccine receives Chinese approval

Novel GP IIb/IIIa antagonists from Millennium

New share issue at Medivir; update on Cathepsin and ME-609 projects

Ganymed and U. of Rotterdam cooperate on identification of new MS pathogens

Angiotech licenses technologies from U. of British Columbia

Chewable Zyrtec tablets approved for pediatric patients

New MAO-B inhibitors and their use claimed by Roche researchers

Novel Itk inhibitors with potential in immune, inflammatory and allergic disorders

BMS team prepares and tests HCV NS5A inhibitors

Lilly claims benzimidazol-based p38 inhibitors for cancer and rheumatoid arthritis

Novel NPY antagonists covered by Roche patent

Two series of GlyT inhibitors under study at Sanofi-Synthelabo

Prous Science announces publication of a comprehensive review on restless legs syndrome

Good safety and efficacy profile of BIBN-4096BS in acute migraine

Safety and pharmacokinetics of the ribavirin prodrug viramidine in healthy volunteers

Increased risk for schizophrenia associated with celiac disease

Imiquimod reported safe and effective in the treatment of solar keratosis

New data indicate mechanism of action of Immunitin

Meta-analysis compares onset of action of antidepressants

Lexapro as effective as Paxil for generalized anxiety disorder

Tripep identifies alpha-HGA analogues against HIV

Roche selects Genmab antibodies as clinical candidates

Chiron discontinues development of tezacitabine

Ezetimibe/simvastatin tablets approved in Mexico

New phase II study investigates Tarceva in poor performance NSCLC patients

Antisoma updates progress of two anticancer drug candidates

Biogen Idec highlights 2003 developments

Axcan Pharma highlights recent developments

ArQule provides R&D program update